ArticlePloS one2012
New fusion transcripts identified in normal karyotype acute myeloid leukemia.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Identification of cryptic KMT2A-PTD and other novel fusion genes by transcriptome sequencing alters molecular risk stratification in AML-NK.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Circular and Fusion RNAs in Medulloblastoma Development.Cancers · 2022Article
- Article
- A Zebrafish Model for a Rare Genetic Disease Reveals a Conserved Role for FBXL3 in the Circadian Clock System.International journal of molecular sciences · 2022Article
- Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.Blood advances · 2021Article
- Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.Blood advances · 2021Article
- Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.Leukemia · 2020Article
- Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia.Cancers · 2019Article
- Fusion Transcripts of Adjacent Genes: New Insights into the World of Human Complex Transcripts in Cancer.International journal of molecular sciences · 2019Review
- NFATC3-PLA2G15 Fusion Transcript Identified by RNA Sequencing Promotes Tumor Invasion and Proliferation in Colorectal Cancer Cell Lines.Cancer research and treatment · 2019Article
- The Oncogenic Potential of SUV39H2: A Comprehensive and Perspective View.Journal of Cancer · 2019Review
- Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies.Journal of oncology · 2019Review
- Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.The New England journal of medicine · 2018Article
- Chimeric RNAs and their implications in cancer.Current opinion in genetics & development · 2018Review
- Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.Journal of clinical medicine · 2017Review
- Intergenically Spliced Chimeric RNAs in Cancer.Trends in cancer · 2016Review
- Recurrent chimeric fusion RNAs in non-cancer tissues and cells.Nucleic acids research · 2016Article
- Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors.Oncotarget · 2016Article
- INTEGRATE: gene fusion discovery using whole genome and transcriptome data.Genome research · 2016Article
- [The second generation sequencing technology and its application in the field of hematologic malignancies].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
Abstract
Genetic aberrations contribute to acute myeloid leukemia (AML). However, half of AML cases do not contain the well-known aberrations detectable mostly by cytogenetic analysis, and these cases are classified as normal karyotype AML. Different outcomes of normal karyotype AML suggest that this subgroup of AML could be genetically heterogeneous. But lack of genetic markers makes it difficult to further study this subgroup of AML. Using paired-end RNAseq method, we performed a transcriptome analysis in 45 AML cases including 29 normal karyotype AML, 8 abnormal karyotype AML and 8 AML without karyotype informaiton. Our study identified 134 fusion transcripts, all of which were formed between the partner genes adjacent in the same chromosome and distributed at different frequencies in the AML cases. Seven fusions are exclusively present in normal karyotype AML, and the rest fusions are shared between the normal karyotype AML and abnormal karyotype AML. CIITA, a master regulator of MHC class II gene expression and truncated in B-cell lymphoma and Hodgkin disease, is found to fuse with DEXI in 48% of normal karyotype AML cases. The fusion transcripts formed between adjacent genes highlight the possibility that certain such fusions could be involved in oncological process in AML, and provide a new source to identify genetic markers for normal karyotype AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.